Provided by Tiger Trade Technology Pte. Ltd.

Hillhouse Capital Holdings

4,734.96
-46.2729-0.97%
Number of Gainers:16
Number of Losers:46
Number of Flat:3
PE:- -
High:4,795.85
Open:4,781.18
Low:4,711.20
Close:4,781.23
Volume:354.77M
Turnover:33.95B
Market Cap:8.46T
Float Cap:8.00T

Loading ...

XPeng Inc. (NYSE:XPEV) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Simply Wall St.
·
Aug 28

Top Premarket Gainers

MT Newswires Live
·
Aug 28

Regenxbio Climbs as New Director Buys Nearly $1 Million of Stock

Reuters
·
Aug 28

Salesforce Stock Price Forecast: 23% Surge Shatters SaaS Pessimism, Can CRM Hit $300?

TradingKey
·
Aug 28

Social Buzz: Wallstreetbets Stocks Lower Pre-Bell Friday; Nvidia, Marvell Technology to Decline

MT Newswires Live
·
Aug 28

Cytokinetics Phase 3 Trial Shows Aficamten Improves Heart Disease Symptoms

MT Newswires Live
·
Aug 28

Morning BID Americas-Six Months and Counting

Reuters
·
Aug 28

Nomura Cuts Price Target on Bilibili to $18 From $22.50, Keeps Neutral Rating

MT Newswires Live
·
Aug 28

Melco Resorts Finance Q2 FY26 Net Income Rises to Us$29.5 Million; Revenue Falls 8.3% to Us$1.07 Billion

Reuters
·
Aug 28

Cytokinetics Shares up 1.4% Premarket After Co Presents New Late-Stage Data for Heart Drug at European Society of Cardiology

THOMSON REUTERS
·
Aug 28

KE Holdings Spends $2M on Share Buyback in Late August

Stock News
·
Aug 28

Cytokinetics to File FDA sNDA for Aficamten in Non-Obstructive HCM in Q4 2026

Reuters
·
Aug 28

Cytokinetics Plans to Submit Supplemental NDA to U.S. FDA for Aficamten in Q4 2026

Reuters
·
Aug 28

Cytokinetics Announces Positive Results from Acacia-HCM Presented in Hot Line Session at the European Society of Cardiology (Esc) Congress 2026 and Published in the New England Journal of Medicine

THOMSON REUTERS
·
Aug 28

Cytokinetics: Plans to Submit Supplemental Nda to U.S. FDA for Aficamten for Treatment of Adult Patients with Symptomatic Nhcm in Q4

THOMSON REUTERS
·
Aug 28

Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine

GlobeNewswire
·
Aug 28

Loop Capital Adjusts Price Target on Salesforce to $250 From $210, Maintains Hold Rating

MT Newswires Live
·
Aug 28

MINISO Group's Half-Year Profit Rises 6.1% to RMB962 Million on Strong Revenue Growth

Stock News
·
Aug 28

Miniso Q2 Adjusted Earnings Fall, Revenue Rises; Shares Up Pre-Bell

MT Newswires Live
·
Aug 28

MINISO Group Holding Q2 Adj. EPS $0.26 Misses $0.30 Estimate, Sales $856.364M Miss $856.700M Estimate

Benzinga Earnings
·
Aug 28